PRESIDENT, DRUG DEV SOLUTIONS Smith Patrick F converted options into 7,151 shares and covered exercise/tax liability with 1,742 shares, increasing direct ownership by 11% to 55,500 units (SEC Form 4)

$CERT
Computer Software: Prepackaged Software
Technology
Get the next $CERT alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SMITH PATRICK F

(Last) (First) (Middle)
C/O CERRTARA, INC.
4 RADNOR CORPORATE CENTER, SUITE 350

(Street)
RADNOR PA 19087

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Certara, Inc. [ CERT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT, DRUG DEV SOLUTIONS
3. Date of Earliest Transaction (Month/Day/Year)
10/04/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/04/2024 M 7,151 A $0(1) 57,242 D
Common Stock 10/04/2024 F 1,742(2) D $10.99 55,500 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 10/04/2024 M 7,151 (1) 10/05/2026 Common Stock 7,151 $0 14,303 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") was granted on October 5, 2023, under the Certara, Inc. ("Certara") 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on October 4, 2024. The remaining two-thirds of the RSUs are scheduled to vest and settle in equal parts on October 5, 2025, and October 5, 2026.
2. Represents RSUs of Certara withheld to satisfy tax withholding obligations in connection with the vesting of RSUs described in footnote 1, exempt under Rule 16b-3.
/s/ Daniel Corcoran, as Attorney-in-Fact for Patrick F. Smith 10/07/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CERT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CERT

DatePrice TargetRatingAnalyst
2/27/2025$16.00Buy
TD Cowen
9/27/2024$16.00Neutral → Buy
UBS
4/10/2024$23.00Sector Weight → Overweight
KeyBanc Capital Markets
4/4/2024Mkt Perform
JMP Securities
2/26/2024$19.00Market Perform
Leerink Partners
12/7/2023$17.00Neutral
UBS
12/5/2023Sector Weight
KeyBanc Capital Markets
8/22/2023$24.50 → $17.00Buy → Hold
Jefferies
More analyst ratings

$CERT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

    RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • Certara Reports Fourth Quarter 2024 Financial Results

    RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%. Software revenue was $42.3 million, compared to $33.6 million in the fourth quarter of 2023, representing growth of 26%.Services revenue was $58.1 million, compared to $54.4 million in the fourth quarter of 2023, representing growth of 7%. Net income was $6.6 million, compared to a net loss of $12.5 million in the fourth quarter of 2023.Adjuste

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

    RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced that company management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceDate and Time: Tuesday

    $CERT
    Computer Software: Prepackaged Software
    Technology

$CERT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CERT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CERT
SEC Filings

See more

$CERT
Leadership Updates

Live Leadership Updates

See more
  • Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

    RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • Certara Appoints John Reynders as New Independent Board Member

    RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • MaxCyte Appoints Cynthia Collins to its Board of Directors

    ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

    $CERT
    $MXCT
    $PSTX
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$CERT
Financials

Live finance-specific insights

See more
  • Certara Reports Fourth Quarter 2024 Financial Results

    RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%. Software revenue was $42.3 million, compared to $33.6 million in the fourth quarter of 2023, representing growth of 26%.Services revenue was $58.1 million, compared to $54.4 million in the fourth quarter of 2023, representing growth of 7%. Net income was $6.6 million, compared to a net loss of $12.5 million in the fourth quarter of 2023.Adjuste

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

    RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara also announced that company management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceDate and Time: Tuesday

    $CERT
    Computer Software: Prepackaged Software
    Technology
  • Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

    Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 millionConfirms Adjusted EBITDA within Guidance Range of $120 million to $124 million RADNOR, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced revenue and bookings for the fourth quarter and full year of fiscal year 2024 based on a preliminary review of fourth quarter results. Preliminary financials for the fourth quarter of 2024 are expected to be as follows: Revenue of $99.7 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 13%. Software revenue of $41.6 million, compared to $33.6 million in th

    $CERT
    Computer Software: Prepackaged Software
    Technology

$CERT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more